AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Have missiles from the Iranian-backed Houthis discovered a loophole in Israeli air defenses?
2
Israeli fintech Morning acquired for $150 million by Italy's TeamSystem
3
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
4
SQream CEO Ami Gal steps down after 14 years
5
Amazon-backed robotics startup BionicHIVE shuts down with $18M debt
More news

Teva

20 stories about Teva
חברת ה תרופות טבע Teva

Teva Agrees to Stop Selling Amgen Generic Following Patent Infringement Settlement

03.01.19|Lilach Baumer
In December, Teva reached a confidential settlement and licensing agreement with drug manufacturer Neos Therapeutics, regarding its generic version for Neos' ADHD drug
מטה טבע פתח תקווה

Teva Reaches Confidential Patent Settlement with Neos

27.12.18|CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
פפרצי מטה טבע בפתח תקווה

Teva Chooses New Israeli Headquarters in Tel Aviv

16.12.18|Micky Grunfeld and Tzally Greenberg
The company will relocate from Petah Tikva, 8 kilometers east of Tel Aviv, to northeastern Tel Aviv neighborhood Ramat HaHayal in mid-2020
תרופה מזרק אפיפן מיילן אלרגיה

Teva, Mylan Drop on Announcement of Epinephrine Injector Rival

09.12.18|Lilach Baumer
Novartis’ U.S. division Sandoz announced a planned release for early 2019. The company will sell its drug, which lacks the EpiPen’s auto-injector, for $250 a pair out of pocket, compared to Mylan and Teva’s $300
מטה טבע פתח תקווה

Teva's Swiss Anti-Nausea Drug Patent Suit Reaches U.S. Supreme Court

05.12.18|Lilach Baumer
Teva was sued in 2011 by Swiss drug company Helsinn Healthcare over its intention to develop a generic version of Helsin's drug, which it released in the U.S. in March 2018
מטה טבע פתח תקווה

Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug

29.11.18|Lilach Baumer
Called Truxima, the drug has been approved to treat several conditions of non-Hodgkin’s lymphoma
בריאות דיגיטלית מדעי החיים רפואה טיפול 2

Sanara Ventures Announces Winners of Healthcare Startup Competition

28.11.18|CTech
The Israel-based accelerator and incubator is backed by Teva and Philips
תרופה מזרק אפיפן מיילן אלרגיה

Teva’s Generic EpiPen Now Available in the U.S. in Limited Numbers

28.11.18|Lilach Baumer
In August, the Israel-headquartered drugmaker won approval to market the first generic EpiPen auto-injectors in the U.S.
מטה טבע פתח תקווה

Teva Up on NYSE Following Morgan Stanley Stock Recommendation Upgrade

05.11.18|CTech
Morgan Stanley increased its price target for the generic drugmaker from $20 to $27
קאר שולץ מנכל טבע

Teva Ups Guidance on Third Quarter Results

01.11.18|Lilach Baumer
Teva reported revenues of $4.5 billion for the quarter, down from $4.7 billion in the second quarter of 2018, and a 19.6% decrease year-over-year
מייקל היידן מחקר ו פיתוח טבע

Former Teva Executives Raise $60 Million for Metabolic Disorders Venture

28.10.18|Lilach Baumer
The company’s pipeline of biologic and small molecule drug candidates was acquired from Teva
מנכ"ל טבע החדש קור שולץ 1

U.S. Benefit Manager Express Scripts Snubs Teva Migraine Injection, Report Says

18.10.18|Lilach Baumer
A Wednesday Reuters report revealed the U.S. company will cover drugs by Eli Lilly and Amgen, but not by Teva
הפגנה עובדי טבע קריית שמונה

Kibbutz-Owned Food Manufacturer Maabarot Bids for Teva’s North Israel Facility

16.10.18|Golan Hazani
Last week, Calcalist reported that Teva was nearing the sale of its Kiryat Shmona facility to German pharmaceutical device company B. Braun
הפגנה עובדי טבע קריית שמונה

Teva Nearing Sale of Israeli Manufacturing Plant

09.10.18|Golan Hazani
The pharmaceutical company is negotiating the sale of a manufacturing facility located in the town Kiryat Shmona in the north of Israel
קאר שולץ מנכל טבע

Teva Investors Are Back on the Rollercoaster

27.09.18|Lilach Baumer
The stock of Teva Pharmaceutical Industries Ltd. fell over 11% on NYSE between September 20 and Thursday, bringing a halt to a nearly two weeks rally
קאר שולץ מנכל טבע

Teva Shares Rise Following FDA Approval of Migraine Drug

16.09.18|Dror Reich
Teva’s new migraine drug is forecasted to bring in $500 million in sales annually
קאר שולץ מנכל טבע

Available Cash Prompts Teva to Make $400 Million Debt Tender Offer

05.09.18|Lilach Baumer
The drugmaker is offering to pay senior notes due 2019 and 2020 in cash
הפגנה מפגינים פיטורים טבע אשדוד

Teva Outsources Manufacturing in Anticipation of Israeli Plant Closure

27.08.18|Golan Hazani
The debt-laden drugmaker announced an aggressive reorganization plan in December, consisting of wide-spread asset divestments and layoffs, including in its home country of Israel
תלמידים כיתה בית ספר לימודים ילדים

Teva’s EpiPen Won’t Hit U.S. Market in Time for School Year, Report Says

26.08.18|Dror Reich
The Israeli drugmaker received approval for a first generic version of Mylan’s auto-injector earlier this month
מטה טבע פתח תקווה

Teva Wins FDA Approval for First Generic EpiPen

19.08.18|Lilach Baumer
EpiPens were sold for less than $60 when Mylan acquired the injectors in 2007. Market Monopoly enabled the company to hike its price up to around $300 a unit today
Previous ArticlesMore Articles